Refusal of Venous Thromboembolism Prophylaxis and Incidence of Thrombosis in Patients with Cystic Fibrosis
DOI:
https://doi.org/10.17140/PRRMOJ-4-138Keywords:
Cystic fibrosis, Prophylaxis, Pulmonary, Anticoagulation, Clinical pharmacyAbstract
Background: Patients with cystic fibrosis (CF) are at risk of venous thromboembolism (VTE) during hospitalization but many refuse VTE prophylaxis.
Methods: A single-center, retrospective medical record review was conducted to determine the refusal rate of pharmacologic VTE prophylaxis in adult patients with CF and to identify any correlation between patients who refused prophylaxis and the incidence of VTE.
Results: Of the 426 patient encounters screened, 307 were included, representing 144 unique patients, with a mean age of 28.4±8.9 years. Venous thromboembolism prophylaxis was refused in 77.5% of the patient encounters. Refusal rates were similar for both unfractionated heparin and enoxaparin (78.8% vs. 75.0%). Five patients (1.63%) developed a VTE during hospitalization or within 30 days of discharge; all five patients refused VTE prophylaxis.
Conclusions: The majority of hospitalized patients with CF refused pharmacologic prophylaxis with no difference in refusal between pharmacologic agents, and the combined incidence of VTE was low.
References
Cayley WE Jr. Preventing deep vein thrombosis in hospi-tal inpatients. BMJ. 2007; 335(7611): 147-151. doi: 10.1136/ bmj.39247.542477.AE
Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Anti-thrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Sup-pl): 338S-400S. doi: 10.1378/chest.126.3_suppl.338S
Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(Suppl 2): e195S-e226S. doi: 10.1378/chest.11-2296
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic ther-apy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(Suppl 2): e419S-494S. doi: 10.1378/chest.11-2301
Mahan CE, Spyropoulos AC. ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients. Am J Health Syst Pharm. 2012 69(24): 2174-2190. doi: 10.2146/ajhp120236
Anderson FA Jr., Spencer FA. Risk factors for venous throm-boembolism. Circulation. 2003; 107(23 Suppl 1): I9-I16. doi: 10.1161/01.CIR.0000078469.07362.E6
Chopra V, Anand S, Hickner A, et al. Risk of venous throm-boembolism associated with peripherally inserted central cath-eters: A systematic review and meta-analysis. Lancet. 2013 382(9889): 311-325. doi: 10.1016/s0140-6736(13)60592-9
Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med. 2000; 160(6): 809- 815. doi: 10.1001/archinte.160.6.809
Williams V, GriffithsAB,Yap ZL, et al. Increased thrombophilic Tendency in pediatric cystic fibrosis patients. Clin Appl Thromb Hemost. 2010; 16(1): 71-76. doi: 10.1177/1076029609334627
Mermis JD, Strom JC, Greenwood JP, et al. Quality improve-ment initiative to reduce deep vein thrombosis associated with peripherally inserted central catheters in adults with cystic fibro-sis. Ann Am Thorac Soc. 2014; 11(9): 1404-1410. doi: 10.1513/ AnnalsATS.201404-175OC
Raffini LJ, Raybagkar D, Blumenstein MS, Rubenstein RC, Manno CS. Cystic fibrosis as a risk factor for recurrent venous thrombosis at a pediatric tertiary care hospital. J Pediatr. 2006; 148(5): 659-664. doi: 10.1016/j.jpeds.2005.11.032
Takemoto CM. Venous thromboembolism in cystic fibro-sis. Pediatr Pulmonol. 2012; 47(2): 105-112. doi: 10.1002/ ppul.21566
WilliamsV, GriffithsAB,Yap ZL, et al. Increased thrombophil-ic tendency in pediatric cystic fibrosis patients. Clin Appl Thromb Hemost.2010; 16(1): 71-76. doi: 10.1177/1076029609334627
Aitken ML, Tonelli MR. Complications of indwelling cath-eters in cystic fibrosis. Chest. 2000; 118(6): 1598-1602. doi: 10.1378/chest.118.6.1598
Kariyawasam HH, Pepper JR, Hodson ME, Geddes DM. Experience of totally implantable venous access devices (TIV ADs) in adults with cystic fibrosis over a 13-year period. Respir Med. 2000; 94(12): 1161-1165. doi: 10.1053/rmed.2000.0943
Nash EF, Helm EJ, Stephenson A, Tullis E. Incidence of deep vein thrombosis associated with peripherally inserted cen-tral catheters in adults with cystic fibrosis. J Vasc Interv Radiol, 2009; 20(3): 347-351. doi: 10.1016/j.jvir.2008.11.018
Munck A, Kheniche A, Alberti C. Central venous thrombosis and thrombophilia in cystic fibrosis: A prospective study. J Cyst Fibros. 2015; 14(1): 97-103. doi: 10.1016/j.jcf.2014.05.015
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pulmonary Research and Respiratory Medicine (PRRM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
